Power Versus Temperature Controlled Ablation for Treatment of VT
NCT: NCT06028919 · COMPLETED
Brief Summary
Ventricular Tachycardia (VT) is a life threatening heart rhythm that comes from the bottom chambers of the heart (the ventricles) and is a leading cause of sudden cardiac death. The majority of patients that are at risk of VT or suffer a cardiac arrest will have an Internal Cardiac Defibrillator (ICD) in situ to treat the abnormal heart rhythm. The ICD can deliver a painful shock to restore normal heart rhythm but importantly does not treat the underlying cause. Current treatment for the prevention of recurrent VT include catheter ablation (CA) or medication. Long-term results with global 12 month VT-free survival rates with CA are around 50%. The trial is to compare 2 different types of ablation catheter that are used to cauterise small areas of unhealthy tissue within the heart that are responsible for VT: Diamond Temp (DT) and Tacticath/Tactiflex (TF). Our hypothesis is that the DT ablation catheter will provide comparable efficacy and safety for the treatment of VT as the current industry gold standard (TF).
Frequently Asked Questions
What is Power Versus Temperature Controlled Ablation for Treatment of VT?
Power Versus Temperature Controlled Ablation for Treatment of VT is a clinical trial registered under NCT06028919. Current status: COMPLETED.
What is the status of NCT06028919?
The current status of NCT06028919 (Power Versus Temperature Controlled Ablation for Treatment of VT) is: COMPLETED.
When did Power Versus Temperature Controlled Ablation for Treatment of VT start?
Power Versus Temperature Controlled Ablation for Treatment of VT started on 2022-09-26.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.